BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gisbert JP, Chaparro M. Safety of anti-TNF agents during pregnancy and breastfeeding in women with inflammatory bowel disease. Am J Gastroenterol. 2013;108:1426-1438. [PMID: 23752881 DOI: 10.1038/ajg.2013.171] [Cited by in Crossref: 84] [Cited by in F6Publishing: 78] [Article Influence: 10.5] [Reference Citation Analysis]
Number Citing Articles
1 Bar-Gil Shitrit A, Grisaru-Granovsky S, Ben Ya'acov A, Goldin E. Management of Inflammatory Bowel Disease During Pregnancy. Dig Dis Sci 2016;61:2194-204. [PMID: 27068171 DOI: 10.1007/s10620-016-4139-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
2 Ternant D, Bejan-Angoulvant T, Passot C, Mulleman D, Paintaud G. Clinical Pharmacokinetics and Pharmacodynamics of Monoclonal Antibodies Approved to Treat Rheumatoid Arthritis. Clin Pharmacokinet 2015;54:1107-23. [PMID: 26123705 DOI: 10.1007/s40262-015-0296-9] [Cited by in Crossref: 63] [Cited by in F6Publishing: 54] [Article Influence: 12.6] [Reference Citation Analysis]
3 Magro F, Abreu C. Immunisations in Crohn's disease: Who? Why? What? When? Best Practice & Research Clinical Gastroenterology 2014;28:485-96. [DOI: 10.1016/j.bpg.2014.04.007] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
4 Mahadevan U, Matro R. Care of the Pregnant Patient With Inflammatory Bowel Disease. Obstetrics & Gynecology 2015;126:401-12. [DOI: 10.1097/aog.0000000000000978] [Cited by in Crossref: 16] [Cited by in F6Publishing: 4] [Article Influence: 2.7] [Reference Citation Analysis]
5 Afzali A. Inflammatory bowel disease during pregnancy: management of a disease flare or remission. Current Opinion in Gastroenterology 2019;35:281-7. [DOI: 10.1097/mog.0000000000000541] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
6 Ling J, Koren G. Challenges in vaccinating infants born to mothers taking immunoglobulin biologicals during pregnancy. Expert Review of Vaccines 2016;15:239-56. [DOI: 10.1586/14760584.2016.1115351] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.2] [Reference Citation Analysis]
7 Chaudrey KH, Kane SV. Safety of Immunomodulators and Anti-TNF Therapy in Pregnancy. Curr Treat Options Gastro 2015;13:77-89. [DOI: 10.1007/s11938-014-0037-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
8 Yu A, Friedman S, Ananthakrishnan AN. Incidence and Predictors of Flares in the Postpartum Year Among Women With Inflammatory Bowel Disease. Inflamm Bowel Dis 2020;26:1926-32. [PMID: 31895410 DOI: 10.1093/ibd/izz313] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 9.0] [Reference Citation Analysis]
9 Leung Y, Panaccione R, Ghosh S, Seow CH. Management of the pregnant inflammatory bowel disease patient on anti-tumour necrosis factor: state of the art and future directions. Can J Gastroenterol Hepatol 2014;28:505-9. [PMID: 25101334 DOI: 10.1155/2014/967598] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
10 Huang VW, Habal FM. From conception to delivery: Managing the pregnant inflammatory bowel disease patient. World J Gastroenterol 2014; 20(13): 3495-3506 [PMID: 24707132 DOI: 10.3748/wjg.v20.i13.3495] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
11 Simonetti O, Rizzetto G, Molinelli E, Diotallevi F, Radi G, Cirioni O, D'Errico MM, Offidani A. Safety and Efficacy of Vaccines during COVID-19 Pandemic in Patients Treated with Biological Drugs in a Dermatological Setting. Healthcare (Basel) 2021;9:401. [PMID: 33916122 DOI: 10.3390/healthcare9040401] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
12 Spini A, Giudice V, Brancaleone V, Morgese MG, De Francia S, Filippelli A, Ruggieri A, Ziche M, Ortona E, Cignarella A, Trabace L. Sex-tailored pharmacology and COVID-19: Next steps towards appropriateness and health equity. Pharmacol Res 2021;173:105848. [PMID: 34454035 DOI: 10.1016/j.phrs.2021.105848] [Reference Citation Analysis]
13 Birru Talabi M, Clowse MEB. Antirheumatic medications in pregnancy and breastfeeding. Curr Opin Rheumatol. 2020;32:238-246. [PMID: 32205567 DOI: 10.1097/bor.0000000000000710] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 12.0] [Reference Citation Analysis]
14 Gomollón F. Seguridad en el diagnóstico y tratamiento de la enfermedad inflamatoria intestinal. Gastroenterología y Hepatología 2013;36:15-20. [DOI: 10.1016/s0210-5705(13)70049-9] [Cited by in Crossref: 3] [Article Influence: 0.4] [Reference Citation Analysis]
15 Porter ML, Lockwood SJ, Kimball AB. Update on biologic safety for patients with psoriasis during pregnancy. Int J Womens Dermatol 2017;3:21-5. [PMID: 28492050 DOI: 10.1016/j.ijwd.2016.12.003] [Cited by in Crossref: 40] [Cited by in F6Publishing: 29] [Article Influence: 10.0] [Reference Citation Analysis]
16 Ananthakrishnan AN, Cheng A, Cagan A, Cai T, Gainer VS, Shaw SY, Churchill S, Karlson EW, Murphy SN, Kohane I, Liao KP. Mode of childbirth and long-term outcomes in women with inflammatory bowel diseases. Dig Dis Sci 2015;60:471-7. [PMID: 25213079 DOI: 10.1007/s10620-014-3353-6] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 2.7] [Reference Citation Analysis]
17 Ngian GS, Briggs AM, Ackerman IN, Van Doornum S. Safety of anti-rheumatic drugs for rheumatoid arthritis in pregnancy and lactation. Int J Rheum Dis 2016;19:834-43. [PMID: 27125255 DOI: 10.1111/1756-185X.12860] [Cited by in Crossref: 15] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
18 Picardo S, Seow CH. A Pharmacological Approach to Managing Inflammatory Bowel Disease During Conception, Pregnancy and Breastfeeding: Biologic and Oral Small Molecule Therapy. Drugs 2019;79:1053-63. [PMID: 31183768 DOI: 10.1007/s40265-019-01141-w] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
19 Knickelbein JE, Jaworski L, Hasan J, Kaushal P, Sen HN, Nussenblatt RB. Therapeutic options for the treatment of non-infectious uveitis. Expert Review of Ophthalmology 2015;10:359-73. [DOI: 10.1586/17469899.2015.1047826] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
20 Chaparro M, Verreth A, Lobaton T, Gravito-soares E, Julsgaard M, Savarino E, Magro F, Biron AI, Lopez-serrano P, Casanova MJ, Gompertz M, Vitor S, Arroyo M, Pugliese D, Zabana Y, Vicente R, Aguas M, Shitrit BA, Gutierrez A, Doherty GA, Fernandez-salazar L, Cadilla MJ, Huguet JM, O'toole A, Stasi E, Marcos MN, Villoria A, Karmiris K, Rahier JF, Rodriguez C, Palomares DM, Fiorino G, Benitez JM, Principi M, Naftali T, Taxonera C, Mantzaris G, Sebkova L, Iade B, Lissner D, Bradley FI, Roman LA, Marin-jimenez I, Merino O, Sierra M, Van Domselaar M, Caprioli F, Guerra I, Peixe P, Piqueras M, Rodriguez-lago I, Ber Y, van Hoeve K, Torres P, Gravito-soares M, Rudbeck-resdal D, Bartolo O, Peixoto A, Martin G, Armuzzi A, Garre A, Donday MG, de Carpi MFJ, Gisbert JP. Long-Term Safety of In Utero Exposure to Anti-TNFα Drugs for the Treatment of Inflammatory Bowel Disease: Results from the Multicenter European TEDDY Study. American Journal of Gastroenterology 2018;113:396-403. [DOI: 10.1038/ajg.2017.501] [Cited by in Crossref: 84] [Cited by in F6Publishing: 77] [Article Influence: 28.0] [Reference Citation Analysis]
21 Biancone L, Annese V, Ardizzone S, Armuzzi A, Calabrese E, Caprioli F, Castiglione F, Comberlato M, Cottone M, Danese S, Daperno M, D’incà R, Frieri G, Fries W, Gionchetti P, Kohn A, Latella G, Milla M, Orlando A, Papi C, Petruzziello C, Riegler G, Rizzello F, Saibeni S, Scribano ML, Vecchi M, Vernia P, Meucci G, Aratari A, Bossa F, Cappello M, Cassinotti A, Chiriatti A, Fiorino G, Formica V, Guidi L, Losco A, Mocciaro F, Onali S, Pastorelli L, Pica R, Principi M, Renna S, Ricci C, Rispo A, Rogai F, Sarmati L, Scaldaferri F, Spina L, Tambasco R, Testa A, Viscido A. Safety of treatments for inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). Digestive and Liver Disease 2017;49:338-58. [DOI: 10.1016/j.dld.2017.01.141] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 6.5] [Reference Citation Analysis]
22 Campanati A, Paolinelli M, Diotallevi F, Martina E, Molinelli E, Offidani A. Pharmacodynamics OF TNF α inhibitors for the treatment of psoriasis. Expert Opin Drug Metab Toxicol 2019;15:913-25. [PMID: 31623470 DOI: 10.1080/17425255.2019.1681969] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
23 Freeman HJ. Developments in the treatment of moderate to severe ulcerative colitis: focus on adalimumab. Ther Clin Risk Manag. 2013;9:451-456. [PMID: 24235838 DOI: 10.2147/TCRM.S38852] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
24 Zhang-Jian SJ, Yang HY, Chiu MJ, Chou IJ, Kuo CF, Huang JL, Yeh KW, Wu CY. Pregnancy outcomes and perinatal complications of Asian mothers with juvenile idiopathic arthritis - a case-control registry study. Pediatr Rheumatol Online J 2020;18:9. [PMID: 31973755 DOI: 10.1186/s12969-020-0404-8] [Reference Citation Analysis]
25 Elshazzly M, Bashjawish F, Shahid MA, Marrero DA, Horowitz J. A Challenging Case of Retroperitoneal Abscess in a Post-Partum Crohn's Disease Patient. Am J Case Rep 2018;19:773-7. [PMID: 29961750 DOI: 10.12659/AJCR.909545] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
26 Giller A, Andrawus M, Gutman D, Atzmon G. Pregnancy as a model for aging. Ageing Res Rev 2020;62:101093. [PMID: 32502628 DOI: 10.1016/j.arr.2020.101093] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
27 Kucharzik T, Ellul P, Greuter T, Rahier JF, Verstockt B, Abreu C, Albuquerque A, Allocca M, Esteve M, Farraye FA, Gordon H, Karmiris K, Kopylov U, Kirchgesner J, MacMahon E, Magro F, Maaser C, de Ridder L, Taxonera C, Toruner M, Tremblay L, Scharl M, Viget N, Zabana Y, Vavricka S. ECCO Guidelines on the Prevention, Diagnosis, and Management of Infections in Inflammatory Bowel Disease. J Crohns Colitis 2021;15:879-913. [PMID: 33730753 DOI: 10.1093/ecco-jcc/jjab052] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
28 Plavšić I, Stimac T, Hauser G. Crohn's disease in women. Int J Womens Health 2013;5:681-8. [PMID: 24204175 DOI: 10.2147/IJWH.S38083] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
29 Weber-Schoendorfer C, Oppermann M, Wacker E, Bernard N, Beghin D, Cuppers-Maarschalkerweerd B, Richardson JL, Rothuizen LE, Pistelli A, Malm H, Eleftheriou G, Kennedy D, Kadioglu Duman M, Meister R, Schaefer C; network of French pharmacovigilance centres. Pregnancy outcome after TNF-α inhibitor therapy during the first trimester: a prospective multicentre cohort study. Br J Clin Pharmacol 2015;80:727-39. [PMID: 25808588 DOI: 10.1111/bcp.12642] [Cited by in Crossref: 93] [Cited by in F6Publishing: 86] [Article Influence: 15.5] [Reference Citation Analysis]
30 Gisbert JP, Marín AC, Chaparro M. Systematic review: factors associated with relapse of inflammatory bowel disease after discontinuation of anti-TNF therapy. Aliment Pharmacol Ther. 2015;42:391-405. [PMID: 26075832 DOI: 10.1111/apt.13276] [Cited by in Crossref: 56] [Cited by in F6Publishing: 54] [Article Influence: 9.3] [Reference Citation Analysis]
31 Cao RH, Grimm MC. Pregnancy and medications in inflammatory bowel disease. Obstet Med 2021;14:4-11. [PMID: 33995565 DOI: 10.1177/1753495X20919214] [Reference Citation Analysis]
32 Cunningham MW, Jayaram A, Deer E, Amaral LM, Vaka VR, Ibrahim T, Cornelius DC, LaMarca B. Tumor necrosis factor alpha (TNF-α) blockade improves natural killer cell (NK) activation, hypertension, and mitochondrial oxidative stress in a preclinical rat model of preeclampsia. Hypertens Pregnancy 2020;39:399-404. [PMID: 32646252 DOI: 10.1080/10641955.2020.1793999] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
33 Govani SM, Wiitala WL, Stidham RW, Saini SD, Hou JK, Feagins LA, Sussman JB, Higgins PD, Waljee AK. Age Disparities in the Use of Steroid-sparing Therapy for Inflammatory Bowel Disease. Inflamm Bowel Dis 2016;22:1923-8. [PMID: 27416039 DOI: 10.1097/MIB.0000000000000817] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 4.3] [Reference Citation Analysis]
34 Doherty G, Katsanos KH, Burisch J, Allez M, Papamichael K, Stallmach A, Mao R, Berset IP, Gisbert JP, Sebastian S, Kierkus J, Lopetuso L, Szymanska E, Louis E. European Crohn's and Colitis Organisation Topical Review on Treatment Withdrawal ['Exit Strategies'] in Inflammatory Bowel Disease. J Crohns Colitis. 2018;12:17-31. [PMID: 28981623 DOI: 10.1093/ecco-jcc/jjx101] [Cited by in Crossref: 71] [Cited by in F6Publishing: 57] [Article Influence: 23.7] [Reference Citation Analysis]
35 Pudipeddi A, Kariyawasam V, Haifer C, Baraty B, Paramsothy S, Leong RW. Safety of drugs used for the treatment of Crohn’s disease. Expert Opinion on Drug Safety 2019;18:357-67. [DOI: 10.1080/14740338.2019.1612874] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 8.0] [Reference Citation Analysis]
36 Soh MC, Mackillop L. Biologics in pregnancy - for the obstetrician. Obstet Gynecol 2016;18:25-32. [DOI: 10.1111/tog.12250] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
37 Furer V, Rondaan C, Heijstek MW, Agmon-levin N, van Assen S, Bijl M, Breedveld FC, D'amelio R, Dougados M, Kapetanovic MC, van Laar JM, de Thurah A, Landewé RB, Molto A, Müller-ladner U, Schreiber K, Smolar L, Walker J, Warnatz K, Wulffraat NM, Elkayam O. 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis 2019;79:39-52. [DOI: 10.1136/annrheumdis-2019-215882] [Cited by in Crossref: 193] [Cited by in F6Publishing: 134] [Article Influence: 96.5] [Reference Citation Analysis]
38 Pagnini C, Arseneau KO, Cominelli F. Safety considerations when using anti-TNFα therapy to treat Crohn's disease. Expert Opin Drug Saf 2015;14:31-44. [PMID: 25400161 DOI: 10.1517/14740338.2015.976610] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
39 Adar T, Grisaru-granovsky S, Ben Ya’acov A, Goldin E, Bar-gil Shitrit A. Pregnancy and the Immune System: General Overview and the Gastroenterological Perspective. Dig Dis Sci 2015;60:2581-9. [DOI: 10.1007/s10620-015-3683-z] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
40 Smeraglia J, Silva JP, Jones K. Improving the sensitivity and specificity of a bioanalytical assay for the measurement of certolizumab pegol. Bioanalysis 2017;9:1217-26. [PMID: 28705025 DOI: 10.4155/bio-2017-0124] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
41 Hart AL, Ng SC. Crohn's disease. Medicine 2015;43:282-90. [DOI: 10.1016/j.mpmed.2015.02.006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
42 Chaparro M, Gisbert JP. Surgery for Crohn's disease during pregnancy: a difficult decision. United European Gastroenterol J 2020;8:633-4. [PMID: 32628893 DOI: 10.1177/2050640620928181] [Reference Citation Analysis]
43 Saavedra Salinas MÁ, Barrera Cruz A, Cabral Castañeda AR, Jara Quezada LJ, Arce-salinas CA, Álvarez Nemegyei J, Fraga Mouret A, Orozco Alcalá J, Salazar Páramo M, Cruz Reyes CV, Andrade Ortega L, Vera Lastra OL, Mendoza Pinto C, Sánchez González A, Cruz Cruz PDR, Morales Hernández S, Portela Hernández M, Pérez Cristóbal M, Medina García G, Hernández Romero N, Velarde Ochoa MDC, Navarro Zarza JE, Portillo Díaz V, Vargas Guerrero A, Goycochea Robles MV, García Figueroa JL, Barreira Mercado E, Amigo Castañeda MC. Guías de práctica clínica para la atención del embarazo en mujeres con enfermedades reumáticas autoinmunes del Colegio Mexicano de Reumatología. Parte II. Reumatología Clínica 2015;11:305-15. [DOI: 10.1016/j.reuma.2014.12.004] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
44 Stone RH, Hong J, Jeong H. Pharmacokinetics of monoclonal antibodies used for inflammatory bowel diseases in pregnant women. J Clin Toxicol 2014;4:209. [PMID: 26539323 DOI: 10.4172/2161-0495.1000209] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
45 Thatiparthi A, Martin A, Liu J, Egeberg A, Wu JJ. Biologic Treatment Algorithms for Moderate-to-Severe Psoriasis with Comorbid Conditions and Special Populations: A Review. Am J Clin Dermatol 2021;22:425-42. [PMID: 33861409 DOI: 10.1007/s40257-021-00603-w] [Reference Citation Analysis]
46 Gisbert JP, Chaparro M. Safety of New Biologics (Vedolizumab and Ustekinumab) and Small Molecules (Tofacitinib) During Pregnancy: A Review. Drugs 2020;80:1085-100. [PMID: 32562207 DOI: 10.1007/s40265-020-01346-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
47 Desalermos AP, Farraye FA, Wasan SK. Vaccinating the inflammatory bowel disease patient. Expert Rev Gastroenterol Hepatol 2015;9:91-102. [PMID: 25160668 DOI: 10.1586/17474124.2014.934672] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
48 Nakase H, Uchino M, Shinzaki S, Matsuura M, Matsuoka K, Kobayashi T, Saruta M, Hirai F, Hata K, Hiraoka S, Esaki M, Sugimoto K, Fuji T, Watanabe K, Nakamura S, Inoue N, Itoh T, Naganuma M, Hisamatsu T, Watanabe M, Miwa H, Enomoto N, Shimosegawa T, Koike K. Evidence-based clinical practice guidelines for inflammatory bowel disease 2020. J Gastroenterol 2021;56:489-526. [PMID: 33885977 DOI: 10.1007/s00535-021-01784-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 8.0] [Reference Citation Analysis]
49 Chebli JM, Gaburri PD, Chebli LA, da Rocha Ribeiro TC, Pinto AL, Ambrogini Júnior O, Damião AO. A guide to prepare patients with inflammatory bowel diseases for anti-TNF-α therapy. Med Sci Monit 2014;20:487-98. [PMID: 24667275 DOI: 10.12659/MSM.890331] [Cited by in Crossref: 20] [Cited by in F6Publishing: 10] [Article Influence: 2.9] [Reference Citation Analysis]
50 Gaidos JK, Kane SV. Overcoming challenges of treating inflammatory bowel disease in pregnancy. Expert Rev Clin Immunol 2016;12:871-8. [PMID: 26981845 DOI: 10.1586/1744666X.2016.1166958] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
51 Matro R, Martin CF, Wolf D, Shah SA, Mahadevan U. Exposure Concentrations of Infants Breastfed by Women Receiving Biologic Therapies for Inflammatory Bowel Diseases and Effects of Breastfeeding on Infections and Development. Gastroenterology 2018;155:696-704. [DOI: 10.1053/j.gastro.2018.05.040] [Cited by in Crossref: 61] [Cited by in F6Publishing: 52] [Article Influence: 20.3] [Reference Citation Analysis]
52 Lee KE, Jung SA, Park SH, Moon CM, Shim SY, Kim ES, Cho SJ, Kim SE, Cho KB, Yang SK. Influence of anti-tumor necrosis factor-alpha therapy to pregnant inflammatory bowel disease women and their children's immunity. Intest Res 2019;17:237-43. [PMID: 30727711 DOI: 10.5217/ir.2018.00071] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
53 Clowse ME, Wolf DC, Förger F, Cush JJ, Golembesky A, Shaughnessy L, De Cuyper D, Mahadevan U. Pregnancy Outcomes in Subjects Exposed to Certolizumab Pegol. J Rheumatol 2015;42:2270-8. [DOI: 10.3899/jrheum.140189] [Cited by in Crossref: 51] [Cited by in F6Publishing: 42] [Article Influence: 8.5] [Reference Citation Analysis]
54 Samaan M, Campbell S, Cunningham G, Tamilarasan AG, Irving PM, McCartney S. Biologic therapies for Crohn's disease: optimising the old and maximising the new. F1000Res 2019;8:F1000 Faculty Rev-1210. [PMID: 31448080 DOI: 10.12688/f1000research.18902.1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
55 El Miedany Y, Palmer D. Rheumatology-led pregnancy clinic: enhancing the care of women with rheumatic diseases during pregnancy. Clin Rheumatol 2020;39:3593-601. [PMID: 32495228 DOI: 10.1007/s10067-020-05173-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
56 Romanowska-Próchnicka K, Felis-Giemza A, Olesińska M, Wojdasiewicz P, Paradowska-Gorycka A, Szukiewicz D. The Role of TNF-α and Anti-TNF-α Agents during Preconception, Pregnancy, and Breastfeeding. Int J Mol Sci 2021;22:2922. [PMID: 33805757 DOI: 10.3390/ijms22062922] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
57 Salat D, Llop R, Aguilera C, Danés I, Bosch M, Asensio C, Castañeda F, Esterlich E, Vallano A. Therapeutic enquiries about biological agents as a tool to identify safety aspects and patterns of use. Eur J Hosp Pharm 2016;23:161-5. [PMID: 31156839 DOI: 10.1136/ejhpharm-2015-000770] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
58 Schleiss MR. Cytomegalovirus in the neonate: immune correlates of infection and protection. Clin Dev Immunol 2013;2013:501801. [PMID: 24023565 DOI: 10.1155/2013/501801] [Cited by in Crossref: 45] [Cited by in F6Publishing: 46] [Article Influence: 5.6] [Reference Citation Analysis]
59 Schulze H, Esters P, Dignass A. Review article: the management of Crohn's disease and ulcerative colitis during pregnancy and lactation. Aliment Pharmacol Ther 2014;40:991-1008. [PMID: 25200000 DOI: 10.1111/apt.12949] [Cited by in Crossref: 33] [Cited by in F6Publishing: 25] [Article Influence: 4.7] [Reference Citation Analysis]
60 Dulai PS, Mosli M, Khanna R, Levesque BG, Sandborn WJ, Feagan BG. Vedolizumab for the treatment of moderately to severely active ulcerative colitis. Pharmacotherapy 2015;35:412-23. [PMID: 25884529 DOI: 10.1002/phar.1561] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
61 Ye TY, Mei Y, Bao DN, Zhu YF, Xu XH, Zhu LF. Maternal anti-tumour necrosis factor-α drug use during pregnancy and risk of infection in the offspring: A systematic review and meta-analysis. Dig Liver Dis 2021;53:1112-7. [PMID: 33376073 DOI: 10.1016/j.dld.2020.11.033] [Reference Citation Analysis]
62 Pons M, Dougados M, Costedoat-Chalumeau N, Briot K, Goupille P, Roux C, Molto A. Pregnancy rates and outcomes in early axial spondyloarthritis: An analysis of the DESIR cohort. Joint Bone Spine 2021;88:105075. [PMID: 32947013 DOI: 10.1016/j.jbspin.2020.09.007] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
63 Matsuoka K, Kobayashi T, Ueno F, Matsui T, Hirai F, Inoue N, Kato J, Kobayashi K, Kobayashi K, Koganei K, Kunisaki R, Motoya S, Nagahori M, Nakase H, Omata F, Saruta M, Watanabe T, Tanaka T, Kanai T, Noguchi Y, Takahashi KI, Watanabe K, Hibi T, Suzuki Y, Watanabe M, Sugano K, Shimosegawa T. Evidence-based clinical practice guidelines for inflammatory bowel disease. J Gastroenterol. 2018;53:305-353. [PMID: 29429045 DOI: 10.1007/s00535-018-1439-1] [Cited by in Crossref: 184] [Cited by in F6Publishing: 164] [Article Influence: 61.3] [Reference Citation Analysis]
64 Chaparro M, Gisbert JP. How safe is infliximab therapy during pregnancy and lactation in inflammatory bowel disease? Expert Opinion on Drug Safety 2014;13:1749-62. [DOI: 10.1517/14740338.2014.959489] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
65 . ACOG Committee Opinion No. 776: Immune Modulating Therapies in Pregnancy and Lactation. Obstetrics & Gynecology 2019;133:e287-95. [DOI: 10.1097/aog.0000000000003176] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 7.5] [Reference Citation Analysis]
66 Hammad I, Porter TF. An Update on Biologic Agents During Pregnancy. Clin Perinatol. 2020;47:733-742. [PMID: 33153658 DOI: 10.1016/j.clp.2020.08.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
67 Leroy C, Rigot JM, Leroy M, Decanter C, Le Mapihan K, Parent AS, Le Guillou AC, Yakoub-Agha I, Dharancy S, Noel C, Vantyghem MC. Immunosuppressive drugs and fertility. Orphanet J Rare Dis 2015;10:136. [PMID: 26490561 DOI: 10.1186/s13023-015-0332-8] [Cited by in Crossref: 84] [Cited by in F6Publishing: 72] [Article Influence: 14.0] [Reference Citation Analysis]
68 Laube R, Paramsothy S, Leong RW. Use of medications during pregnancy and breastfeeding for Crohn's disease and ulcerative colitis. Expert Opin Drug Saf 2021;20:275-92. [PMID: 33412078 DOI: 10.1080/14740338.2021.1873948] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
69 Hyrich KL, Verstappen SM. Biologic therapies and pregnancy: the story so far. Rheumatology (Oxford). 2014;53:1377-1385. [PMID: 24352337 DOI: 10.1093/rheumatology/ket409] [Cited by in Crossref: 73] [Cited by in F6Publishing: 59] [Article Influence: 9.1] [Reference Citation Analysis]
70 Armuzzi A, Lionetti P, Blandizzi C, Caporali R, Chimenti S, Cimino L, Gionchetti P, Girolomoni G, Lapadula G, Marchesoni A, Marcellusi A, Mennini FS, Salvarani C, Cimaz R. anti-TNF agents as therapeutic choice in immune-mediated inflammatory diseases: focus on adalimumab. Int J Immunopathol Pharmacol 2014;27:11-32. [PMID: 24774504 DOI: 10.1177/03946320140270S102] [Cited by in Crossref: 38] [Cited by in F6Publishing: 23] [Article Influence: 5.4] [Reference Citation Analysis]
71 Mariette X, Förger F, Abraham B, Flynn AD, Moltó A, Flipo RM, van Tubergen A, Shaughnessy L, Simpson J, Teil M, Helmer E, Wang M, Chakravarty EF. Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study. Ann Rheum Dis 2018;77:228-33. [PMID: 29030361 DOI: 10.1136/annrheumdis-2017-212196] [Cited by in Crossref: 140] [Cited by in F6Publishing: 107] [Article Influence: 35.0] [Reference Citation Analysis]
72 Hassid B, Mahadevan U. The use of biologic therapy in pregnancy: a gastroenterologist's perspective. Curr Opin Rheumatol 2014;26:347-53. [PMID: 24625373 DOI: 10.1097/BOR.0000000000000048] [Cited by in Crossref: 17] [Cited by in F6Publishing: 2] [Article Influence: 2.4] [Reference Citation Analysis]
73 Holcomb ZE, Porter ML, Kimball AB. A safety review of biologic therapies for the management of hidradenitis suppurativa and unmet needs. Expert Opin Drug Saf 2021;:1-15. [PMID: 33910441 DOI: 10.1080/14740338.2021.1924147] [Reference Citation Analysis]
74 Horst S, Kane S. The use of biologic agents in pregnancy and breastfeeding. Gastroenterol Clin North Am 2014;43:495-508. [PMID: 25110255 DOI: 10.1016/j.gtc.2014.05.005] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
75 Nguyen GC, Seow CH, Maxwell C, Huang V, Leung Y, Jones J, Leontiadis GI, Tse F, Mahadevan U, van der Woude CJ; IBD in Pregnancy Consensus Group; Canadian Association of Gastroenterology. The Toronto Consensus Statements for the Management of Inflammatory Bowel Disease in Pregnancy. Gastroenterology. 2016;150:734-757.e1. [PMID: 26688268 DOI: 10.1053/j.gastro.2015.12.003] [Cited by in Crossref: 224] [Cited by in F6Publishing: 189] [Article Influence: 37.3] [Reference Citation Analysis]
76 Chaparro M, Donday MG, Abad-Santos F, Martín de Carpi FJ, Maciá-Martínez MÁ, Montero D, Acosta D, Brenes Y, Gisbert JP. The safety of drugs for inflammatory bowel disease during pregnancy and breastfeeding: the DUMBO registry study protocol of GETECCU. Therap Adv Gastroenterol 2021;14:17562848211018097. [PMID: 34158835 DOI: 10.1177/17562848211018097] [Reference Citation Analysis]
77 Jung SA. Concerns in pregnancy and childbirth of women with inflammatory bowel disease. Intest Res 2016;14:107-8. [PMID: 27175109 DOI: 10.5217/ir.2016.14.2.107] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
78 Soh MC, Nelson-piercy C. High-risk pregnancy and the rheumatologist. Rheumatology 2015;54:572-87. [DOI: 10.1093/rheumatology/keu394] [Cited by in Crossref: 48] [Cited by in F6Publishing: 32] [Article Influence: 6.9] [Reference Citation Analysis]